JM
Ultra-pure synthetic cannabidiol
We’re utilising our scientific and manufacturing expertise to develop and commercialise ultra-pure synthetic cannabinoids that meet the quality requirements demanded by the pharmaceutical industry.
Eugene McKenna
Increasing momentum in policy and investment to grow the hydrogen economy
Where are we with hydrogen right now? JM's Managing Director, Green Hydrogen speaks to Climate Action.
Various
A bright future for hydrogen
In this article, JM's Eugene McKenna and Andy Walker tell the New Statesman why the UK could be a leader in clean hydrogen technology.
JM
Crystallisation process development
A whitepaper featuring a solid form expert, detailing crystallisation process development in the manufacture of active pharmaceutical ingredients (APIs)
JM
Early form screening strategies to accelerate candidate selection
A whitepaper featuring a solid form expert, detailing early form screening strategies for pharmaceutical development and the importance of understanding an API’s solid form for formulation development.
Various
Catalysts for collaboration
Demand for greener, more sustainable technologies in the pharma, agro and fine chemicals sectors is growing – catalysis is at the heart of this transformation.
Ahir Pushpanath
The elements of life: catalysing pharmaceutical innovation
JM's Ahir Pushpanath gives a fascinating insight into JM's developments in biocatalysis as he explores how enzymes' unique catalytic abilities drive science by connecting essential life elements.
JM
The importance of solid form science in modern drug development
As the pharmaceutical industry turns to more complex chemical entities with increased molecular weight, enhancing solubility is becoming a key drug development challenge.
Joanna Clark
Building the battery of the future – today
In this article, New Scientist delve deeper into our next generation cathode material, eLNO.
Load More
